JUNIOR STRENGTH ADVIL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for JUNIOR STRENGTH ADVIL (JUNIOR STRENGTH ADVIL).
Non-selective cyclooxygenase (COX-1 and COX-2) inhibition, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
| Metabolism | Hepatic metabolism primarily via CYP2C9; also involves glucuronidation; major metabolites are hydroxylated and carboxylated forms. |
| Excretion | Primarily renal (90% as glucuronide conjugates and 10% unchanged); <5% biliary/fecal. |
| Half-life | 2-4 hours (terminal); prolonged in hepatic impairment and elderly. |
| Protein binding | 90-99% bound to albumin; concentration-dependent. |
| Volume of Distribution | 0.1-0.2 L/kg (low, consistent with high protein binding). |
| Bioavailability | Oral: 85-95% (ibuprofen susp/liquid); 80-100% (tablets/capsules). |
| Onset of Action | Oral: 15-30 minutes; peak effect 1-2 hours. |
| Duration of Action | 4-6 hours (analgesic/antipyretic); 6-8 hours (anti-inflammatory at higher doses). |
| Molecular Weight | 206.28 |
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for OTC use.
| Dosage form | TABLET, CHEWABLE |
| Renal impairment | eGFR 30-60 mL/min: reduce dose by 50% or extend interval to q8-12h; eGFR <30 mL/min: avoid use. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and monitor; Child-Pugh C: avoid use. |
| Pediatric use | 5-10 mg/kg/dose orally every 6-8 hours; maximum 40 mg/kg/day (or 1200 mg/day) for children ≥6 months. |
| Geriatric use | Start at lowest effective dose (200 mg q6-8h); maximum 1200 mg/day; monitor renal function and GI bleeding risk. |
| 1st trimester | Use is generally avoided unless benefits outweigh risks; associated with increased risk of miscarriage and cardiac defects if used near implantation. Ibuprofen is not recommended in first trimester due to potential for oligohydramnios and fetal renal impairment. |
| 2nd trimester | Use with caution; may cause oligohydramnios and fetal renal dysfunction. Avoid prolonged use or high doses. Ibuprofen is not preferred in second trimester; use only if clearly needed. |
| 3rd trimester | Contraindicated after 30 weeks gestation due to risk of premature closure of ductus arteriosus and oligohydramnios. Use should be avoided in third trimester. |
Clinical note
Comprehensive clinical and safety monograph for JUNIOR STRENGTH ADVIL (JUNIOR STRENGTH ADVIL).
| Placental transfer | Ibuprofen crosses the placenta; fetal concentrations can reach up to 10% of maternal plasma levels. Transfer is passive and dependent on maternal dose and gestational age. |
| Breastfeeding |
■ FDA Black Box Warning
No FDA boxed warning for JUNIOR STRENGTH ADVIL (ibuprofen). However, NSAIDs in general carry a boxed warning for cardiovascular thrombotic events and gastrointestinal bleeding.
| Common Effects | Nausea Headache Flatulence Diarrhea |
| Serious Effects |
Hypersensitivity to ibuprofen or any componentHistory of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDsActive peptic ulcer disease or gastrointestinal bleedingSevere hepatic or renal impairmentThird trimester of pregnancy (especially after 30 weeks gestation)Perioperative pain in the setting of coronary artery bypass graft (CABG) surgeryKnown severe uncontrolled heart failure
| Precautions | Cardiovascular risk: Increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, Gastrointestinal risk: Increased risk of GI bleeding, ulceration, and perforation, Renal effects: May cause renal impairment, especially in patients with pre-existing renal disease, Hypersensitivity reactions: Anaphylaxis, bronchospasm, Fluid retention and edema, Avoid use with other NSAIDs or in late pregnancy (risk of premature closure of ductus arteriosus) |
Loading safety data…
| Ibuprofen is excreted into breast milk in very low amounts (0.0008% of maternal dose). It is generally considered compatible with breastfeeding, but caution is advised in infants with known sensitivity to NSAIDs or with thrombocytopenia. The American Academy of Pediatrics considers ibuprofen compatible with breastfeeding. |
| Lactation Rating | L1 (Safest) in LactRisk database; generally considered compatible. |
| Teratogenic Risk | Avoid during third trimester due to risk of premature closure of ductus arteriosus, oligohydramnios, and fetal renal dysfunction. First and second trimester use only if clearly needed; limited human data suggest low risk of major malformations but increased risk of miscarriage and cardiac defects. |
| Fetal Monitoring | Monitor fetal heart rate, amniotic fluid index, and ductus arteriosus patency with ultrasound if used in third trimester. Assess maternal renal function, bleeding time, and platelet count with prolonged therapy. |
| Fertility Effects | Reversible inhibition of ovulation due to inhibition of prostaglandin synthesis. Use may delay or impair fertility in women attempting conception; discontinue use if difficulty conceiving. |
| Food/Dietary | Avoid alcohol: increases risk of GI bleeding. Limit caffeine as may increase side effects. Can be taken with food or milk to minimize GI irritation. |
| Clinical Pearls | For pediatric patients, weight-based dosing is critical; typical dose is 5-10 mg/kg/dose every 6-8 hours. Avoid use in children with dehydration, bleeding disorders, or aspirin allergy. May mask signs of infection. Not recommended for children under 6 months. |
| Patient Advice | Give with food or milk to reduce stomach upset. · Do not exceed recommended dose; overdose can cause liver damage or gastrointestinal bleeding. · Do not use with other products containing ibuprofen or NSAIDs. · Shake suspension well before measuring dose using appropriate dosing device. · Stop use and consult doctor if symptoms worsen or new symptoms occur. · Keep out of reach of children; in case of overdose, contact Poison Control immediately. |